Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Cost of RevenueEBIATGross ProfitLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Dna X (SONM) Shares Outstanding (2018 - 2025)

Dna X filings provide 8 years of Shares Outstanding readings, the most recent being $1.3 million for Q4 2025.

  • On a quarterly basis, Shares Outstanding rose 356.9% to $1.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.3 million, a 356.9% increase, with the full-year FY2025 number at $1.3 million, up 356.9% from a year prior.
  • Shares Outstanding hit $1.3 million in Q4 2025 for Dna X, up from $1.0 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $40.7 million in Q3 2022 to a low of $245952.0 in Q4 2023.
  • Median Shares Outstanding over the past 5 years was $4.3 million (2023), compared with a mean of $7.6 million.
  • Biggest five-year swings in Shares Outstanding: tumbled 93.97% in 2023 and later soared 356.9% in 2025.
  • Dna X's Shares Outstanding stood at $18.8 million in 2021, then tumbled by 78.32% to $4.1 million in 2022, then tumbled by 93.97% to $245952.0 in 2023, then increased by 12.58% to $276881.0 in 2024, then soared by 356.9% to $1.3 million in 2025.
  • The last three reported values for Shares Outstanding were $1.3 million (Q4 2025), $1.0 million (Q3 2025), and $574353.0 (Q2 2025) per Business Quant data.